Studio	Promotore	Data Parere Unico CE	Documenti
Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial)	ASUR-AV5 Ascoli Piceno	08/04/2020	https://www.aifa.gov.it/documents/20142/1131319/Hydro-Stop_Documenti.zip
A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22).	F. Hoffmann-La Roche Ltd	30/03/3020	https://www.aifa.gov.it/documents/20142/1131319/Tocilizumab_Documenti.zip
Uno studio randomizzato multicentrico in aperto per valutare l'efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19 (RCT-TCZ-COVID-19).	Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia	27/03/2020	https://www.aifa.gov.it/documents/20142/1131319/RCT-TCZ-COVID19_documenti.zip
An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19).	sanofi-aventis Recherche & Développement	26/03/2020	https://www.aifa.gov.it/documents/20142/1131319/Sarilumab_documenti.zip
A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101).	SOBI	25/03/2020	https://www.aifa.gov.it/documents/20142/1131319/Sobi.IMMUNO-101_documenti.zip
Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19).	Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale – Via M. Semmola 80131 Napoli	22/03/2020	https://www.aifa.gov.it/documents/20142/1131319/TOCIVID-19_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study)	Gilead Sciences, Inc	11/03/2020	https://www.aifa.gov.it/documents/20142/1131319/GS-US-540-5774_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)	Gilead Sciences, Inc	11/03/2020	https://www.aifa.gov.it/documents/20142/1131319/GS-US-540-5773_documenti.zip